# QSP Glioblastoma v1.0 â€” rAAV/shRNA Gene Therapy Dashboard

> **A quantitative systems pharmacology (QSP) model of glioblastoma (GBM) implementing the DNA-PK/MYT1L-CXCR1-ERK1/2 positive feedback loop with rAAV-delivered shRNA gene therapy intervention.**

![Status](https://img.shields.io/badge/status-active-4ADE80?style=flat-square)
![Model](https://img.shields.io/badge/model-13--state%20ODE%20RK4-A855F7?style=flat-square)
![Solver](https://img.shields.io/badge/solver-in--browser-67E8F9?style=flat-square)
![License](https://img.shields.io/badge/license-All%20Rights%20Reserved-F87171?style=flat-square)

---

## Overview

![Dashboard Overview](figures/fig0_overview.png)

This tool models the self-sustaining positive feedback loop in GBM:

```
CXCR1 ligands (IL-8/GROÎ±)
      â†“  binds
    CXCR1 receptor
      â†“  activates
    ERK1/2 (pERK)          â† Loop Node 1
      â†“  phosphorylates
    DNA-PK (pDNA-PK)       â† Loop Node 2
      â†“  phosphorylates
    MYT1L (pMYT1L)         â† Loop Node 3
      â†“  transactivates CXCR1 promoter
    CXCR1  â—„â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ loop closes
```

rAAV-delivered shRNA targeting CXCR1, DNA-PK, or MYT1L disrupts this loop, collapsing GBM proliferation by removing the autocrine amplification driving tumour growth.

---

## Simulation Results

### GBM Tumour Burden & shRNA Pharmacokinetics

![GBM Tumour Burden & shRNA](figures/fig1_gbm_shrna.png)

The model runs a **90-day burn-in** to reach physiological steady state before therapy begins. Four intratumoral rAAV injections (â–¶ orange dashed lines) drive progressive shRNA accumulation. The treated arm diverges sharply from control, reaching near-complete regression by day 60.

---

### Feedback Loop Node Activity â€” ERK1/2, DNA-PK, MYT1L

![Loop Node Activity](figures/fig2_loop_nodes.png)

shCXCR1 acts post-transcriptionally â€” knocking down **all CXCR1 mRNA** regardless of MYT1L-driven transcription. This collapses the upstream cascade: pERK1/2 â†’ pDNA-PK â†’ pMYT1L all fall in concert, preventing the loop from re-engaging even at high MYT1L activity.

---

### Feedback Loop Intensity & Immune Compartment

![Loop Intensity & Immune](figures/fig3_loop_immune.png)

**Left:** The composite loop intensity index (CXCR1 Ã— ERK Ã— DNAPK Ã— MYT1L) is suppressed ~67% in the treated arm, confirming loop disruption rather than partial attenuation.

**Right:** CTL activity is preserved or enhanced post-treatment as TGF-Î² immunosuppression falls with GBM burden. TAM M2 polarisation decreases in parallel, partially reversing the immune escape axis.

---

## Metrics Scorecard

![Scorecard](figures/fig4_scorecard.png)

| Metric | Result | Target |
|--------|--------|--------|
| GBM treated (endpoint)  | < 20% |
| GBM control (steady state) | 15â€“55% |
| Tumour suppression | â‰¥ 5 pp |
| Loop suppressed | 25â€“95% |
| CTL activity | â‰¥ 0.05 |
| Loop gain (self-sustaining) | â‰¥ 2Ã— |

---

## Experimental Priority Roadmap

![Experimental Roadmap](figures/fig5_roadmap.png)

Eight experiments ranked by predicted leverage on key model outputs. Each entry includes the specific quantitative prediction the experiment would validate or falsify.

---

## Model Architecture

### ODE System (13 state variables)

| # | Variable | Description |
|---|----------|-------------|
| 0 | GBM | Tumour cell fraction |
| 1 | CXCR1 | Receptor expression |
| 2 | pERK1/2 | ERK1/2 phosphorylation |
| 3 | pDNA-PK | DNA-PK phosphorylation |
| 4 | pMYT1L | MYT1L transcription factor |
| 5 | IL-8 | CXCR1 ligand (autocrine) |
| 6 | GROÎ± | CXCR1 ligand (autocrine) |
| 7 | pAKT | Parallel survival signal |
| 8 | TAM M2 | Pro-tumour macrophages |
| 9 | TGF-Î² | Immunosuppressive cytokine |
| 10 | CTL | Cytotoxic T lymphocytes |
| 12 | shRNA | rAAV-delivered knockdown agent |

### Three Coupled Feedback Cycles

| Loop | Nodes | Type | Drug target |
|------|-------|------|-------------|
| DNA-PK/MYT1L-CXCR1 | CXCR1â†’ERKâ†’DNAPKâ†’MYT1Lâ†’CXCR1 | ğŸ”´ Vicious amplifier | shCXCR1 / shDNAPK / shMYT1L |
| TAM-TGF-Î² immune escape | GBMâ†’TGF-Î²â†’TAM M2â†’GBM | ğŸ”´ Vicious amplifier | anti-TGF-Î² |
| CTL protective | CTLâ†’GBM lysisâ†’â†“TGF-Î²â†’CTL | ğŸ’š Protective brake | Preserve |

### Key Design Decisions

**Post-transcriptional shRNA model:**
The shRNA acts on the full CXCR1 production term â€” not just degradation â€” so MYT1L-driven transcription cannot escape knockdown:

```
// Correct: shRNA suppresses all mRNA regardless of promoter
cxcr1_prod = (k_cxcr1_base + hill(pMYT1L, ...)) Ã— (1 âˆ’ kd_frac)

// Wrong: loop floods production, drug can't keep up
cxcr1_deg  = k_deg Ã— CXCR1 Ã— (1 + kd Ã— 3)
```

**CTL recruitment model:**
CTL production is GBM-reactive (tumour antigen-driven), creating a stabilising negative feedback that prevents bistability (0% or 100% GBM only).

**Loop gain metric:**
Measured as CXCR1 fold-induction over ligand-only baseline. Gain â‰¥ 2Ã— = self-sustaining loop.

---

## Features

- âš¡ **Full in-browser RK4 solver** â€” zero installation, runs on any device
- ğŸ”¬ **Pre-ODE loop screening** â€” 2Ã—2 matrix classifier (vicious/virtuous Ã— amplifying/suppressing)
- ğŸ¤– **Auto-optimiser** â€” hill-climbing across 5 biological targets simultaneously
- ğŸ•¸ **Interactive signalling network** â€” vis.js graph with drug target annotations
- ğŸ“Š **10 Plotly charts** â€” all state variables, loop intensity, proliferation decomposition
- ğŸ“„ **PDF export** â€” results report with all charts and metrics
- ğŸ§ª **Experimental roadmap** â€” 8 experiments ranked by model leverage, updated live

---

## Access

**The source code for this tool is available on request.**

> âš ï¸ Unauthorised copying, redistribution, or modification of the source code is prohibited.  
> Â© 2026 tjmb03. All rights reserved.

---

*Built with Plotly.js Â· vis-network Â· pure in-browser RK4 Â· jsPDF Â· html2canvas*
